Is Ki67 still a powerful ally in predicting the clinical benefit of anthracyclines for the adjuvant treatment of early breast cancer?
Crossref DOI link: https://doi.org/10.1007/s10549-017-4630-9
Published Online: 2018-01-06
Published Print: 2018-04
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Bravaccini, Sara http://orcid.org/0000-0002-0075-8538
Rocca, Andrea
Bronte, Giuseppe
Funding for this research was provided by:
Not applicable
License valid from 2018-01-06